Immunologic biomarkers in prostate cancer

References

• Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348:9 - 17; http://dx.doi.org/10.1016/j.jim.2009.06.004; PMID: 19552894
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Papamichail M, Perez SA. Therapeutic cancer vaccines: a long and winding road to success. Expert Rev Vaccines 2014; 13:131 - 41; PMID: 24224539
   PubMed Web of Science ®Google Scholar
• Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN. A new era in anticancer peptide vaccines. Cancer 2010; 116:2071 - 80; PMID: 20187092
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237 - 51; http://dx.doi.org/10.1038/nrc3237; PMID: 22437869
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099 - 105; http://dx.doi.org/10.1200/JCO.2009.25.0597; PMID: 20100959
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663 - 74; http://dx.doi.org/10.1007/s00262-009-0782-8; PMID: 19890632
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501 - 8; http://dx.doi.org/10.1016/S1470-2045(12)70006-2; PMID: 22326924
   PubMed Web of Science ®Google Scholar
• Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F, Thiel RP, Taneja SS. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 2005; 174:2174 - 7; http://dx.doi.org/10.1097/01.ju.0000181205.23233.65; PMID: 16280758
   PubMed Web of Science ®Google Scholar
• Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006; 66:5723 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-3928; PMID: 16740710
   PubMed Web of Science ®Google Scholar
• Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, deVere White RW. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004; 60:257 - 71; http://dx.doi.org/10.1002/pros.20039; PMID: 15176055
   PubMed Web of Science ®Google Scholar
• Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, Datar R, Cote RJ. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int 2006; 97:170 - 8; http://dx.doi.org/10.1111/j.1464-410X.2006.05857.x; PMID: 16336351
   PubMed Web of Science ®Google Scholar
• Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001; 166:1514 - 9; http://dx.doi.org/10.1016/S0022-5347(05)65822-3; PMID: 11547123
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Tortora G, D’Armiento FP, De Rosa G, Staibano S, Autorino R, D’Armiento M, De Laurentiis M, De Placido S, Catalano G, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8:3438 - 44; PMID: 12429632
   PubMed Web of Science ®Google Scholar
• Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD, Wroclawski ER, Del Giglio A. Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol 2010; 184:842 - 50; http://dx.doi.org/10.1016/j.juro.2010.04.077; PMID: 20663525
   PubMed Web of Science ®Google Scholar
• Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113:619 - 28; http://dx.doi.org/10.1002/ijc.20615; PMID: 15472903
   PubMed Web of Science ®Google Scholar
• Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 2007; 25:675 - 81; http://dx.doi.org/10.1200/JCO.2006.07.0649; PMID: 17308272
   PubMed Web of Science ®Google Scholar
• de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007; 25:257 - 62; http://dx.doi.org/10.1200/JCO.2006.07.0888; PMID: 17235043
   PubMed Web of Science ®Google Scholar
• Lara PN Jr., Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004; 100:2125 - 31; http://dx.doi.org/10.1002/cncr.20228; PMID: 15139054
   PubMed Web of Science ®Google Scholar
• Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004; 60:332 - 7; http://dx.doi.org/10.1002/pros.20065; PMID: 15264245
   PubMed Web of Science ®Google Scholar
• Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Cancer Res 2010; 70:2686 - 96; http://dx.doi.org/10.1158/0008-5472.CAN-09-2517; PMID: 20233867
   PubMed Web of Science ®Google Scholar
• Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother 2007; 56:601 - 13; http://dx.doi.org/10.1007/s00262-006-0213-z; PMID: 16960693
   PubMed Web of Science ®Google Scholar
• Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 2007; 121:2031 - 41; http://dx.doi.org/10.1002/ijc.22936; PMID: 17634957
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010; 2:213 - 26; http://dx.doi.org/10.2217/imt.09.89; PMID: 20635929
   PubMed Web of Science ®Google Scholar
• Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther 2006; 6:1311 - 21; http://dx.doi.org/10.1517/14712598.6.12.1311; PMID: 17223739
   PubMed Web of Science ®Google Scholar
• Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008; 26:3426 - 33; http://dx.doi.org/10.1200/JCO.2007.15.7842; PMID: 18612158
   PubMed Web of Science ®Google Scholar
• Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, Papamichail M, Thanos A, von Hofe E, Baxevanis CN. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 2010; 16:3495 - 506; http://dx.doi.org/10.1158/1078-0432.CCR-10-0085; PMID: 20466887
   PubMed Web of Science ®Google Scholar
• Perez SA, Anastasopoulou EA, Tzonis P, Gouttefangeas C, Kalbacher H, Papamichail M, Baxevanis CN. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother 2013; 62:1599 - 608; http://dx.doi.org/10.1007/s00262-013-1461-3; PMID: 23934022
   PubMed Web of Science ®Google Scholar
• Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599 - 613; http://dx.doi.org/10.1093/jnci/djs033; PMID: 22395641
   PubMed Web of Science ®Google Scholar
• Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011; 60:433 - 42; http://dx.doi.org/10.1007/s00262-010-0960-8; PMID: 21221967
   PubMed Web of Science ®Google Scholar
• Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 2012; 61:1243 - 53; http://dx.doi.org/10.1007/s00262-012-1201-0; PMID: 22258792
   PubMed Web of Science ®Google Scholar
• Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, et al. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008; 14:3372 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-4433; PMID: 18519766
   PubMed Web of Science ®Google Scholar